Abstract
Survivors of pink disease (PD; infantile acrodynia) are a population of clinically identifiable individuals who are Hg sensitive. In the present study, single nucleotide polymorphisms in genes thought to be involved in Hg transport and metabolism were compared across two groups: (i) PD survivors (n = 25); and (ii) age-and sexmatched healthy controls (n = 25).
Results:
Analyses revealed significant differences between groups in genotype frequencies for rs662 in the gene encoding paraoxanase 1 (PON1) and rs1801131 in the gene encoding methylenetetrahydrofolate reductase (MTHFR).
Conclusions:
We have identified two genetic polymorphisms associated with increased sensitivity to Hg. Genetic variation in MTHFR and 
INTRODUCTION
The potent neurotoxicity of mercury (Hg) has been known for centuries, yet it remains in use in a variety of medical, commercial, and industrial practices. Of most concern internationally is the fact that Hg is widely distributed throughout our food chain, air, water, and land at levels that have proven toxic to flora, fauna, and human beings. [1] Hg in all its forms (ionic Hg and Hg /Hg ; vapor Hg and organic alkyl forms MeHg , Me Hg, EtHg , and Et Hg) has potent neurotoxicity for the brain and particularly for the human fetal brain.
[2] The central nervous system is a major target of Hg, and both high-and low-dose exposure can produce significant long-term neurological damage. [3, 4] Neurological symptoms attributed to Hg intoxication include ataxia, deafness, psychosis, loss of speech, erethism, and constriction of the visual field. [5] For example, the direct causal link between cerebral palsy and Hg exposure to the developing human fetus was first established by the Swedish Expert Group in 1971[6] and confirmed recently by other researchers. [7, 8] For a fetus, Hg brain levels can be significantly higher than in maternal blood, and the developing fetal brain demonstrates high sensitivity to Hg toxicity. Current research has identified that Hg exposure during early development (including in utero) is associated with tic disorders, [9] PD, [10] cerebral palsy, and Hunter-Russell syndrome. [11] The PD outbreak of the 20 century highlights the potential severity of the reaction (including death) that some children may have to a low level of Hg exposure, [12] and it is a variable, idiosyncratic, and unpredictable individual susceptibility to Hg that determines the reaction. [13] In the early 1900s, the increased availability of new and untested pharmaceuticals led to the exposure of infants to inorganic Hg present as calomel in teething powder. Calomel contained Hg levels low enough to not be poisonous to the average infant; however, for a small subset of the population highly sensitive to Hg, the levels were sufficient to be detrimental and produce symptoms, which would eventually be classified as a disease entity known as PD or infantile acrodynia. [12] [13] tic disorders, [9] and Alzheimer's disease. [14] Additionally, the symptoms of an adverse response to Hg have been known to mimic various conditions including Parkinson's disease, [15] amyotrophic lateral sclerosis, [16] and schizophrenia.
[17] An understanding of the genetic moderators of Hg impact would facilitate testing of these hypotheses.
The toxicokinetics and clinical effects of Hg exposure depend greatly on the dose, pattern, timing, route of exposure, individual excretion rates, and idiosyncratic sensitivity to Hg. [18] There is a substantial body of evidence to show that much of the variance in Hg sensitivity is determined by genetic factors. [3] The aim of this study was to test for association between genetic variation in genes involved in Hg transport and metabolism and PD.
MATERIALS AND METHODS
Ethical approval for this study was granted by the Deakin University Human Research Ethics Committee.
Participants
Survivors of PD: Potential participants were drawn from the database of PD survivors held by the Australian Pink Disease Support Group (http://www.pinkdisease.org/). A recruitment notice was placed on the group's website as well as emailed to all members who had supplied an email address. The notice stipulated that participants must have received a formal diagnosis of PD as a child and be residing within 200km of Sydney or Melbourne, Australia. Following receipt of informed consent from 25 volunteers, a suitable time was arranged for a qualified nurse to visit their residence. Participants had 2 × 10 ml of blood drawn. The blood samples were then transported to Genetic Repositories Australia whereupon cell lines were created. Extracted deoxyribonucleic acid (DNA) was then supplied to the research team. The PD survivor sample ranged in age from 60 to 75 years (22 females and three males) and had a mean age of 65.7 years (SD = 3.9).
Healthy controls: Age-and sex-matched healthy control DNA (n = 25) was procured from the Baker IDI Heart and Diabetes Institute Biobank. The healthy control sample was drawn from 22 females and 3 males ranging in age from 59 to 75 years with a mean age of 65.9 years (SD = 5.3).
For all samples, DNA concentration was adjusted to 50 ng/μl in TE buffer (10mM Tris-HCl, 1mM ethylenediaminetetraacetic acid (EDTA)•Na (pH 8.0)) and stored at −20°C.
Genotyping
Genetic polymorphisms associated with Hg metabolism and toxicity were identified by literature search. Details of the candidate genes associated with increased sensitivity to Hg are shown in Table 1 . A total of 16 polymorphisms were genotyped in this study, 13 of them by polymerase chain reaction (PCR) restriction fragment length polymorphism. Presence/absence of GSTM1 and GSTT1 was assessed by multiplex PCR with albumin as positive control. The 15 bp insertion/deletion polymorphism (rs11267756) in SLC7A5 was assessed by PCR and agarose gel electrophoresis. Table 1 Candidate genes associated with increased sensitivity to Hg Standard PCRs were conducted using 100 ng of DNA, 1 U Taq polymerase (Invitrogen, Melbourne, Australia), 200 μM each dNTP, 0.5 μM forward and reverse primer, 20 mM Tris-HCl pH 8.4, 50 mM KCl, and 2 mM MgCl in a total volume of 20 μl. The multiplex PCR for GSTM1, GSTT1, and albumin was conducted using 100 ng of DNA, 2 U Taq polymerase (Invitrogen), 400 μM each dNTP, 0.3 μM GSTM1 primers, 0.2 μM GSTT1 primers, 0.15 μM albumin primers, 20 mM Tris-HCl pH 8.4, 50 mM KCl, and 3 mM MgCl2 in a total volume of 20 μl.
Following PCR, 10 μl of each PCR product was purified using QIAquick PCR Purification kits (Qiagen, Melbourne, Australia) and eluted in 20 μl of nuclease-free water.
Restriction digestion of purified PCR products was conducted using 10 μl of purified DNA, 5-20 U restriction enzyme, and 1x corresponding restriction enzyme buffer, made up to a total volume of 20 μl with nuclease-free water. Following restriction digestion, the samples were separated using agarose gel electrophoresis (1-5%, depending on product size), labeled with SybrSafe (Invitrogen) and visualized under ultraviolet (UV) light. Genotype calling was conducted blindly by two independent reviewers.
RESULTS
Hardy-Weinberg equilibrium and genotype frequencies for PD survivors and control group participants were compared using Fisher's exact test. Analyses were performed using IBM Statistical Package for Social Sciences (SPSS) 21. Genotype frequencies were considered to be different between groups at P < 0.05. The summary results for all polymorphisms are shown in Table 2 . Table 2 Genotype data for 16 candidate gene polymorphisms in pink disease survivors and matched control subjects
The only significant difference in genotype frequencies between PD survivors and controls were found for methylenetetrahydrofolate reductase (NAD (P) H) (MTHFR) at rs1801131 (χ = 6.13, P = 0.039) and for paraoxonase 1 (PON1) at rs662 (χ = 7.04, P = 0.030). Representative digests for the various genotypes are shown in Figure 1 . Hardy-Weinberg equilibrium was present for all polymorphisms examined, except for rs1801131 in the MTHFR gene (χ = 5.68, P < 0.05) and rs1050450 in GPX1 (χ = 6.17, P < 0.05).
DISCUSSION
The old toxicology adage attributed to Paracelsus, "the dose makes the poison" is an incomplete and insufficient model of toxicokinetics, with modern perspectives emphasizing the large individual variance in response to any given dose of a toxicant. [18] Therefore, in order to comprehensively understand the etiology of clinical syndromes arising from Hg exposure, it is critical to understand individual sensitivity. Here we report the first study of Hg sensitivity based on genetic variance amongst survivors of PD, a condition which is the result of an idiosyncratic sensitivity to Hg. [12] In this study, we found polymorphisms in two genes that differentiated PD survivors from age-and gender-matched healthy control subjects. This suggests a possible role in Hg sensitivity. The associated single nucleotide polymorphisms were rs662, which results in a glutamine to arginine substitution at position 192 of PON1, and rs1801131, which causes a glutamic acid to alanine substitution at amino acid 429 of MTHFR. Neither of these polymorphisms have previously been associated with sensitivity to Hg or other heavy metals, although studies have shown that heavy metals, including Hg, can affect PON1 activity levels. [19] PON1 plays an important role in the hydrolysis and detoxification of several organophosphate insecticides, including diazinon and parathion, the nerve gases sarin and soman, and aromatic esters and lactones. Although no direct role for PON1 in the detoxification of Hg has been demonstrated, it is feasible that it could play a role and that this genetic variation at rs662, which is known to affect enzymatic activity, could affect the ability of the enzyme to protect against the toxic effects of Hg. Previous studies have shown association between genetic polymorphism in PON1 (including rs662) and a range of clinical disorders including coronary artery disease, [20] microvascular complications of diabetes, [21] and macular degeneration. [22] In most cases, these associations are thought to be driven by altered metabolism and levels of oxidized lipids in subjects with genetic variation in PON1.
MTHFR catalyzes the conversion of 5,10-methyle netetrahydrofolate to 5-methyltetrahydrofolate, a cosubstrate for homocysteine remethylation to methionine. This enzyme therefore plays a crucial role in amino acid and folate metabolism. MTHFR deficiency results in homocysteinemia and altered folate metabolism, and it has been studied extensively in the context of a range of diseases. Genetic variation in MTHFR has been reproducibly associated with neural tube defects, [23] vascular disease, [24] cleft lip/palate, [25] interaction between genetic variation in MTHFR and plasma levels of either homocysteine or folate metabolites (or both), suggesting that MTHFR may act as a modifier of disease risk. A limitation of the study was the modest sample size of 50. This figure was a function of both funding limitations and challenges in communicating with and recruiting PD survivors. The PD survivor population is diminishing through age-related mortality, with the youngest survivors born in the 1950s. It is a very small, elderly, and unique population. As a result of the sample size, statistical power was, of course, impacted. Although the statistical analyses conducted were conservative and therefore accounted for the low power, it remains important to note the number of comparisons conducted (16) and interpret the results cautiously in light of the possibility of type I error.
Despite these challenges, the PD survivor population remains, to our knowledge, the only identifiable clinical population of individuals that have a demonstrated history of Hg sensitivity. They remain a vitally important population to researchers aiming to further our understanding of Hg sensitivity. The issue is particularly salient as low level Hg exposure is ubiquitous and the potent neurotoxicity of Hg is well established as being especially devastating to the central and peripheral nervous systems of infants and unborn babies. [3] Beyond this emerging understanding of how Hg may affect individuals at doses known to produce clinical effects, there is less certainty as to predicting who is most at risk, and why, as a result of our lack of understanding of individual difference variables related to Hg sensitivity. This study contributes to our knowledge in this area by identifying two genetic variants that significantly differentiate healthy controls from a clinical population of Hgsensitive individuals. Of course, there are likely many more genetic variables contributing to Hg sensitivity that await identification.
CONCLUSIONS
In this study, we have identified two genetic polymorphisms over 7000 newborns from 16 areas world wide. J Med Genet. 
